Nexentis Technologies (NXTS) Stock Overview
Through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NXTS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nexentis Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.80 |
| 52 Week High | US$89.79 |
| 52 Week Low | US$3.38 |
| Beta | 1.8 |
| 1 Month Change | 7.62% |
| 3 Month Change | -16.02% |
| 1 Year Change | -92.55% |
| 3 Year Change | -99.57% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| NXTS | US Chemicals | US Market | |
|---|---|---|---|
| 7D | -17.2% | 3.1% | 0.9% |
| 1Y | -92.6% | 8.8% | 24.5% |
Return vs Industry: NXTS underperformed the US Chemicals industry which returned 8.6% over the past year.
Return vs Market: NXTS underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| NXTS volatility | |
|---|---|
| NXTS Average Weekly Movement | 17.7% |
| Chemicals Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NXTS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NXTS's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 8 | David Palach | www.nexentistech.com |
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company’s pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems
Nexentis Technologies Inc. Fundamentals Summary
| NXTS fundamental statistics | |
|---|---|
| Market cap | US$3.50m |
| Earnings (TTM) | -US$9.81m |
| Revenue (TTM) | n/a |
Is NXTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXTS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.81m |
| Earnings | -US$9.81m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.6% |
How did NXTS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/14 04:55 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nexentis Technologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.